Dear Fellow Shareholders:
Over the past several months there have been a great number of positive changes in the underlying business of CEL-SCI. These changes have transformed the company from one focused on developing its lead investigational drug, Multikine* (Leukocyte Interleukin, Inj.), for the treatment of head and neck cancer, which represents 6% of the world’s cancer cases, into one that is developing Multikine as an immunotherapy technology platform with the capability to treat multiple diseases, even certain virally induced conditions. The expanded work is being undertaken with a whole new group of partners, including the U.S. Navy, and it provides us tremendous potential to explore and capitalize on multiple opportunities for different potential uses for Multikine. It also allows us to unlock significant value in our company. My own stock purchases in the open market are evidence of my faith in this broader strategy.
Help employers find you! Check out all the jobs and post your resume.
